At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MIRA Mira Pharma
Post-Mkt 10-30 19:22:08 EDT
0.5485
-0.0231
-4.04%
盘后0.5230
-0.0255-4.65%
16:39 EDT
High0.5890Low0.5101Vol207.65K
Open0.5890D1 Closing0.5716Amplitude13.80%
Mkt Cap22.97MTradable Cap21.22MTotal Shares41.88M
T/O113.52KT/O Rate0.54%Tradable Shares38.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mira Pharmaceuticals Reports Significant Weight and Fat Reduction with Oral Skny-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared with Semaglutide
THOMSON REUTERS  ·  10-29 20:00
Mira Pharmaceuticals Reports Significant Weight and Fat Reduction with Oral Skny-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared with Semaglutide
Mira Pharmaceuticals - Announces Positive Proof-of-Concept Results for Skny-1 in Obesity Study
THOMSON REUTERS  ·  10-29 20:00
Mira Pharmaceuticals - Announces Positive Proof-of-Concept Results for Skny-1 in Obesity Study
MIRA unveils promising preclinical data for oral obesity drug
TIPRANKS  ·  10-29 04:50
MIRA unveils promising preclinical data for oral obesity drug
MIRA Pharmaceuticals' Oral SKNY-1 Reduces Weight, Fat in Obese Mice Study
Reuters  ·  10-29 04:03
MIRA Pharmaceuticals' Oral SKNY-1 Reduces Weight, Fat in Obese Mice Study
Mira Pharmaceuticals - Skny-1 Weight Reduction Occurs Without Significant Decrease in Food Consumption - SEC Filing
THOMSON REUTERS  ·  10-29 04:02
Mira Pharmaceuticals - Skny-1 Weight Reduction Occurs Without Significant Decrease in Food Consumption - SEC Filing
Mira Pharmaceuticals - Skny-1-Treated Mice Do not Show Significant Lean-Mass Loss Compared to Semaglutide - SEC Filing
THOMSON REUTERS  ·  10-29 04:02
Mira Pharmaceuticals - Skny-1-Treated Mice Do not Show Significant Lean-Mass Loss Compared to Semaglutide - SEC Filing
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Lucid Diagnostics (LUCD) and MIRA Pharmaceuticals, Inc. (MIRA)
TIPRANKS  ·  10-25
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Lucid Diagnostics (LUCD) and MIRA Pharmaceuticals, Inc. (MIRA)
Mira Pharmaceuticals' MIRA-55 Shows Pain Relief Comparable to Celebrex in Rat Study
Reuters  ·  10-22
Mira Pharmaceuticals' MIRA-55 Shows Pain Relief Comparable to Celebrex in Rat Study
Mira Pharmaceuticals Inc: Mira-55 Also Reduced Inflammation-Associated Swelling and was Well Tolerated, with no Adverse Clinical Signs Observed
THOMSON REUTERS  ·  10-22
Mira Pharmaceuticals Inc: Mira-55 Also Reduced Inflammation-Associated Swelling and was Well Tolerated, with no Adverse Clinical Signs Observed
Mira Pharmaceuticals Reports Mira-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
THOMSON REUTERS  ·  10-22
Mira Pharmaceuticals Reports Mira-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Mira : Advancing Mira-55 Toward a Planned Ind Submission in the First Quarter of 2027
THOMSON REUTERS  ·  10-22
Mira : Advancing Mira-55 Toward a Planned Ind Submission in the First Quarter of 2027
Mira : Once-Daily Oral Mira-55 Reduced Both Mechanical & Thermal Pain Hypersensitivity (P < 0.001 Versus Vehicle) as from Lowest Dose Used
THOMSON REUTERS  ·  10-22
Mira : Once-Daily Oral Mira-55 Reduced Both Mechanical & Thermal Pain Hypersensitivity (P < 0.001 Versus Vehicle) as from Lowest Dose Used
Mira Pharmaceuticals Inc: Results Support Continued Advancement of Mira-55 Toward an Investigational New Drug (Ind) Submission
THOMSON REUTERS  ·  10-22
Mira Pharmaceuticals Inc: Results Support Continued Advancement of Mira-55 Toward an Investigational New Drug (Ind) Submission
MIRA Pharmaceuticals Initiated at Buy by Maxim Group
Dow Jones  ·  09-17
MIRA Pharmaceuticals Initiated at Buy by Maxim Group
MIRA advances Ketamir-2 Phase 2a neuropathy program
TIPRANKS  ·  09-17
MIRA advances Ketamir-2 Phase 2a neuropathy program
Mira advances Ketamir-2 to chemotherapy-induced peripheral neuropathy
TIPRANKS  ·  09-17
Mira advances Ketamir-2 to chemotherapy-induced peripheral neuropathy
MIRA Pharmaceuticals Submits Ketamir-2 Phase 2a CIPN Protocol for IRB Review After FDA Feedback
Reuters  ·  09-17
MIRA Pharmaceuticals Submits Ketamir-2 Phase 2a CIPN Protocol for IRB Review After FDA Feedback
Mira Pharmaceuticals - Targets Site Initiation for Phase 2a Ketamir-2 Study in Q1 2027
THOMSON REUTERS  ·  09-17
Mira Pharmaceuticals - Targets Site Initiation for Phase 2a Ketamir-2 Study in Q1 2027
Mira Pharmaceuticals - Submits Phase 2a Protocol for Ketamir-2 in Cipn to Irb After FDA Review
THOMSON REUTERS  ·  09-17
Mira Pharmaceuticals - Submits Phase 2a Protocol for Ketamir-2 in Cipn to Irb After FDA Review
Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (Cipn) Following FDA Review
THOMSON REUTERS  ·  09-17
Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (Cipn) Following FDA Review

Introduction

Company Name.
Mira Pharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Issue price:
--